Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Faron Pharmaceuticals Oy’s options widen after fund-raising

Demand for shares in Faron Pharmaceuticals Oy’s (LON:FARN) was strong when the company tapped the City last week for £8mln to fund the development of its two lead drugs.
Faron’s chief executive (CEO), Dr Markku Jalkanen, tells Proactive Investors the fund-raising has brought “quite a number of UK institutional investors” on to the shareholder register.
Some of the new funding will pay for a phase I/II trial in the US of Traumakine, its lead product, in patients with a heart condition called rupture of abdominal aorta aneurysm.
“It’s really important for us to get activities on the US side, specifically for our lead product. We want to conduct a safety trial there, which was the advice given by the [US] Food and Drug Administration, and this will take up maybe half of the proceeds raised at this time,” Dr Jalkanen said.
Some has been kept aside for the pre-clinical and early clinical development of Clevegen, an antibody that could help the body’s own immune system tackle cancer.
“Clevegen is becoming more and more interesting,” the CEO said.
Early stage biotechs are no strangers to fund-raising and there may be another share issue in the offing next year but it is not the only option on the table, Dr Jalkanen said, opening up the possibility of partnership or licensing activities.

Meet Faron Pharmaceuticals Ltd, Silence Therapeutics plc and Scancell Holdings Plc at our event, London , 01 November 2018. Register here »
View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

September 12 2018

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use